| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed72333aad4e1aa11a4fa5f8db579132 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122 |
| filingDate |
2019-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8349d282b2c8a390179de002a7b78388
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cb325d3713010b31ea01db39cf15f34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c29573e2c237dce3a31f2f52ce7a6ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65c27aae45e2f22a50cb7517d53207e6 |
| publicationDate |
2019-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110522743-A |
| titleOfInvention |
The application of toifanol as an active ingredient in immunosuppressive agents |
| abstract |
The invention discloses the application of toifanol as an effective ingredient in immunosuppressive agents. The present invention screened out toifanol with significant calmodulin phosphatase (CN) inhibitory activity from silique, and its immunosuppressive effect Comparable to cyclosporin A, a widely used immunosuppressant in clinic, the mechanism of action shows that toifanol exerts immunosuppressive activity by targeting CN/NFAT signaling pathway, and has weak toxicity to spleen cells. of immunosuppressants. |
| priorityDate |
2019-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |